Search results
Methods and results: MERLIN-TIMI 36 randomized patients with non-ST elevation ACS to ranolazine or placebo. Atrial fibrillation episodes detected on continuous electrocardiogram (cECG) monitoring were reviewed in 6351 patients (97% of trial).
- Efficacy of ranolazine in patients with chronic angina observations ...
In this largest study of ranolazine in patients with...
- Efficacy of ranolazine in patients with chronic angina observations ...
Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
19 lip 2010 · In the MERLIN-TIMI 36 trial, 6560 patients hospitalized with NSTEACS were randomized within 48 hours of their last ischemic symptom to ranolazine or placebo in addition to standard medical and interventional therapy. 11 The primary objective of the MERLIN-TIMI 36 trial was to assess the effect of ranolazine on the composite of cardiovascular ...
23 maj 2006 · The ongoing MERLIN TIMI 36 trial, scheduled to be completed in 2006, will address whether ranolazine can reduce the composite end point of cardiovascular death, myocardial infarction, or recurrent ischemia in high-risk patients with an acute coronary syndrome and will provide important data on the adverse event profile and safety in a large ...
25 kwi 2007 · In this large trial that approximately doubles the existing safety experience with ranolazine extended-release, we found that there was no excess of arrhythmias or sudden cardiac death during a median 1-year follow-up in patients treated with ranolazine compared with placebo.
10 wrz 2014 · MERLIN-TIMI 36 randomized patients with non-ST elevation ACS to ranolazine or placebo. Atrial fibrillation episodes detected on continuous electrocardiogram (cECG) monitoring were reviewed in 6351 patients (97% of trial).
28 kwi 2009 · In this largest study of ranolazine in patients with established coronary artery disease, ranolazine was effective in reducing angina with favorable safety in a substantially broader group of patients with angina than previously studied.
